{"success":true,"data":{"pressRelease":{"id":"170364","rtpr_id":"nBwYz7RFa-20261015","ticker":"BEAT","exchange":"NASDAQ","all_tickers":["BEAT"],"title":"HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients","author":"Business Wire","published_at":"2026-10-15T12:31:00.147Z","article_body":"HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG\nMonitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk\nPatients\n\n\n * HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare\nleaders in the EU-funded EXIT-CVD research consortium\n\n * HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies\n\n * HEART-CHECK will evaluate whether HeartBeam’s at-home 3D ECG can help\nclinicians recognize recurrent events earlier in patients recently discharged\nafter ACS\n\nHeartBeam, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heartbeam.com%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=HeartBeam%2C+Inc.&index=1&md5=81d4a658b13c9e85e0495860c8b885b2)\n(NASDAQ: BEAT), a medical technology company focused on transforming cardiac\ncare by providing powerful cardiac insights, today announced it is a\ncontributing partner in the launch of the EXIT-CVD\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fexitcvd.eu%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=EXIT-CVD&index=2&md5=ebb3aae1609bc9d4d21980d854ad088b)\nresearch project, co-funded by the European Union Innovative Health Initiative\n(IHI\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ihi.europa.eu%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=IHI&index=3&md5=7077c59aab765eb05f10cae7d07fa3bb)\n) and industry partners. The research consortium is led by University Medical\nCenter Groningen (UMCG\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.umcg.nl%2Fover-het-umcg&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=UMCG&index=4&md5=ca5aad018997cfbcdf9c00368350eef0)\n) and Royal Philips\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.philips.com%2Fnewscenter&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=Royal+Philips&index=5&md5=088ddbf19aeb64ea1c22e5efad1fd903)\n, and aims to transform how cardiovascular disease is detected, monitored and\ntreated.\n\nWithin EXIT-CVD, the HEART-CHECK study will evaluate the HeartBeam System for\nearly detection and triage of cardiac events in high-risk patients recently\ndischarged after an acute coronary syndrome (ACS), a group with\nwell-documented risk of recurrent ischemic events, arrhythmias and hospital\nreadmissions(1).\n\n“Patients discharged after an ACS are in a vulnerable period, and their\nsymptoms can be atypical and easily dismissed,” said Branislav Vajdic, PhD,\nFounder and President of HeartBeam. “HEART-CHECK gives us the opportunity to\nevaluate whether a clinical-grade ECG recording outside of a medical facility\ncan help clinicians recognize recurrent events earlier and get these patients\nto the right care sooner. Our priority remains FDA clearance for heart attack\nassessment. HEART-CHECK builds on our heart attack detection work, as we\ncontinue to advance opportunities for heart attack assessment outside of the\nhealthcare facility. Being invited to contribute alongside some of the\nworld’s leading cardiovascular institutions and companies affirms the\nimportance of acting at the right point along the cardiac care journey.”\n\nHeartBeam’s role in the EXIT-CVD Consortium\n\nHeartBeam is a contributing partner in the EXIT-CVD consortium and will lead\nthe HEART-CHECK study, one of the project’s 22 clinical studies.\nHeartBeam’s contribution to the consortium is in-kind, including devices and\nclinical team expertise. The HEART-CHECK study is designed as a hybrid\neffectiveness-implementation study, assessing both the HeartBeam System’s\nclinical performance in the intended use population and its integration into\nreal-world care pathways. The HeartBeam System is currently not CE marked and\nwill be evaluated in HEART-CHECK for investigational purposes only.\n\nThe HeartBeam System captures the heart’s electrical signals in three\nnon-coplanar dimensions, delivering clinical-grade ECG data outside the\nhospital. Earlier this month, the U.S. Food and Drug Administration (FDA)\ngranted Breakthrough Device Designation to the HeartBeam System as a tool for\nassessing potential heart attacks at home. The HeartBeam System is currently\nFDA cleared for arrhythmia assessment only. Its use for heart attack\nassessment is investigational only at this time.\n\nEXIT-CVD aims to transform how cardiovascular disease is detected, monitored\nand treated. It will do so by identifying and acting on three key exit points\nalong the cardiac care journey: preventing disease before it develops (early\nexit), reversing disease progression (mid exit), or halting progression in\nadvanced stages (late exit). By combining diagnostics, digital tools and\nadvanced therapeutic approaches, EXIT-CVD aims to deliver actionable,\nevidence-based strategies that can be implemented across diverse healthcare\nsystems in Europe. The research project unites 42 public and private partners\nacross 17 countries to conduct 22 clinical studies involving more than 14,000\npatients. With a total budget of EUR 27.6 million, the project is co-funded by\nthe European Union Innovative Health Initiative (IHI) and industry partners.\n\n“Our vision is a future where heart disease is no longer an irreversible\npathway,” said Professor Pim van der Harst, Project Coordinator of EXIT-CVD\nand Head of Cardiology at the University Medical Center Groningen. “By\nunderstanding both the biological and social drivers of cardiovascular\ndisease, and deploying integrated innovations across diagnostics, monitoring,\nand care, we can empower patients and clinicians to exit the disease continuum\nbefore it’s too late.”\n\n“For more than 30 years, we have viewed cardiovascular disease as a\ncontinuous journey, from risk factors such as hypertension, to\natherosclerosis, a first cardiac event and ultimately, for many patients,\nheart failure,” said Robin Nijveldt, Chief of Cardiology at UMC Utrecht.\n“Yet most of us improve care within our own specialty and rarely have a\ncomplete view of the patient’s experience. EXIT-CVD is an ambitious effort\nto build that holistic view together, helping transform cardiac care for\nmillions of patients across Europe.”\n\nClinical studies\n\nThe EXIT-CVD research consortium will conduct a total of 22 clinical studies\ninvolving more than 14,000 patients across Europe, including:\n\n\n * Remote Cardiac Monitoring After Acute Coronary Syndrome (HEART-CHECK study):\nHybrid effectiveness-implementation study evaluating the HeartBeam System for\nearly detection and triage of acute coronary syndrome in high-risk\ncardiovascular patients.\n\n * Camera-Based In-Hospital Monitoring (CARDIO-CAM study): Deployment and\nevaluation of an unobtrusive, video-based patient monitoring system that\ncontinuously captures cardiorespiratory signals and relevant clinical context.\n\n * Spectral CT for Early Detection, Risk Stratification and Personalized Patient\nCare Pathways (LEADER-PAD study): Development and validation of new approaches\nfor the early detection of cardiovascular disease in asymptomatic and low risk\nsymptomatic patients using spectral CT.\n\n * Nurse/HCP-Led Remote Heart Failure Monitoring (REMODEL-HF study):\nMultinational randomized study evaluating the Heart Failure Management System\n(\nHFMS\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcardiac.zoll.com%2Fmedical-professionals%2Fheart-failure-management-system&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=HFMS&index=6&md5=a8cf3e2993163d4ddb9056004acbe505)\n\n), a non-invasive remote monitoring technology, in patients recently\nhospitalized for heart failure, with the objective of improving outcomes and\noptimizing guideline-directed medical therapy.\n\n * Imaging-Guided PCI Randomized Trial (GUIDANCE-PCCT study): Evaluation of\nclinical and procedural outcomes of PCI guided by photon counting CT versus\nstandard angiography-guided PCI.\n\n * Advanced Imaging in Infiltrative Cardiomyopathies (NOTIFY-2 study): Validation\nof AI-driven image and ECG analysis algorithms to improve early diagnosis of\nLeft Ventricular Hypertrophy (LVH) and underlying disease risk stratification.\n\nConsortium partners\n\nThe IHI EXIT-CVD public-private partnership comprises 42 partner organizations\nfrom 17 countries:\n\n\n * Clinical and academic partners: Hospital de la Santa Creu i Sant Pau (Spain),\nPolitecnico di Milano (Italy), University of Pavia (Italy), Centro\nCardiologico Monzino (Italy), EOC (Switzerland), KU Leuven (Belgium), NIKARD\n(Poland), UMC Utrecht (Netherlands), UMC Groningen (Netherlands), Technical\nUniversity Eindhoven (Netherlands), Universitätsklinikum Köln (Germany),\nKing’s College London (UK), London School of Economics and Political Science\n(UK), and Varsinais-Suomen Hyvinvointialue (Finland)\n\n * Industry partners: Philips, Circle CVI, GE HealthCare, Siemens Healthineers,\nHeartBeam, Medtronic, Huawei, XVIVO Perfusion, AstraZeneca, Cardiomed, Megi\nHealth, Viatris, Cordys, Novartis, Corbotics, ZOLL, Sanofi, Repairon, Johnson\n& Johnson MedTech Heart Recovery, Onsentia, and CogStack\n\n * Healthcare consultancy: Bridg Ou and IQVIA Solutions\n\n * Patient organization: Stichting VrouwenHart\n\n * Medical association: European Society of Cardiology (ESC)\n\nMore information can be viewed on the EXIT-CVD\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fexitcvd.eu%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=EXIT-CVD&index=7&md5=d5b8da513c295c46741b671c0afb9ee7)\nwebsite.\n\nThis project is supported by the Innovative Health Initiative Joint\nUndertaking (IHI JU) under grant agreement No 101253160. The JU receives\nsupport from the European Union's Horizon Europe research and innovation\nprogram and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.\nFunded by the European Union, the private members, and those contributing\npartners of the IHI JU. Views and opinions expressed are those of the\nauthor(s) only and do not necessarily reflect those of the aforementioned\nparties. Neither of the aforementioned parties can be held responsible for\nthem.\n\nAbout HeartBeam, Inc.\n\nHeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to\ntransforming the detection and monitoring of critical cardiac conditions. The\nCompany has developed the first-ever cable-free device capable of collecting\nECG signals in 3D, from three non-coplanar directions, and synthesizing the\nsignals into a 12-Lead ECG. This platform technology is designed for portable\ndevices that can be used wherever the patient is to deliver actionable heart\nintelligence. Physicians will be able to identify cardiac health trends and\nacute conditions and direct patients to the appropriate care – all outside\nof a medical facility, thus redefining the future of cardiac health\nmanagement. HeartBeam’s 3D ECG technology received FDA clearance for\narrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software\nreceived FDA clearance for arrhythmia assessment in December 2025(1). The\nCompany holds over 25 issued patents related to technology enablement. For\nadditional information, visit HeartBeam.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heartbeam.com%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=HeartBeam.com&index=8&md5=5eb9a383b2f58c45e0639bcc77d71d8a)\n.\n\nForward-Looking Statements\n\nAll statements in this release that are not based on historical fact are\n\"forward-looking statements.\" While management has based any forward-looking\nstatements included in this release on its current expectations, the\ninformation on which such expectations were based may change. Forward-looking\nstatements involve inherent risks and uncertainties which could cause actual\nresults to differ materially from those in the forward-looking statements, as\na result of various factors including those risks and uncertainties described\nin the Risk Factors and in Management’s Discussion and Analysis of Financial\nCondition and Results of Operations sections of our Forms 10-K, 10-Q and other\nreports filed with the SEC and available at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=www.sec.gov&index=9&md5=1503a652d53948613704053cc9dfbd1f)\n. We urge you to consider those risks and uncertainties in evaluating our\nforward-looking statements. We caution readers not to place undue reliance\nupon any such forward-looking statements, which speak only as of the date\nmade. Except as otherwise required by the federal securities laws, we disclaim\nany obligation or undertaking to publicly release any updates or revisions to\nany forward-looking statement contained herein (or elsewhere) to reflect any\nchange in our expectations with regard thereto or any change in events,\nconditions or circumstances on which any such statement is based.\n\n(1)Cleared Indications for Use\n\nThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia\nassessment received FDA clearance in December 2025. Refer to the Company’s\nCleared Indications for Use at https://www.heartbeam.com/indications\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heartbeam.com%2Findications&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=https%3A%2F%2Fwww.heartbeam.com%2Findications&index=10&md5=6463cd35978c51d77e0b2e314fd37a99)\nfor details on the intended use of its technology.\n\nMKT-166 v0\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261015343006/en/\n(https://www.businesswire.com/news/home/20261015343006/en/)\n\nMedia Contact: \n\nmedia@heartbeam.com (mailto:media@heartbeam.com)\n\nInvestor Relations Contact: \n\nChris Tyson\n\nExecutive Vice President\n\nMZ North America\n\nDirect: 949-491-8235\n\nBEAT@mzgroup.us \n(mailto:BEAT@mzgroup.us) \nwww.mzgroup.us\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.mzgroup.us%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=www.mzgroup.us&index=11&md5=332013f545ec9fef8335da154ea91295)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwYz7RFa-20261015","title":"HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients","author":"Business Wire","ticker":"BEAT","created":"2026-10-15T12:31:00.147Z","tickers":["BEAT"],"exchange":"NASDAQ","article_body":"HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG\nMonitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk\nPatients\n\n\n * HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare\nleaders in the EU-funded EXIT-CVD research consortium\n\n * HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies\n\n * HEART-CHECK will evaluate whether HeartBeam’s at-home 3D ECG can help\nclinicians recognize recurrent events earlier in patients recently discharged\nafter ACS\n\nHeartBeam, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heartbeam.com%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=HeartBeam%2C+Inc.&index=1&md5=81d4a658b13c9e85e0495860c8b885b2)\n(NASDAQ: BEAT), a medical technology company focused on transforming cardiac\ncare by providing powerful cardiac insights, today announced it is a\ncontributing partner in the launch of the EXIT-CVD\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fexitcvd.eu%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=EXIT-CVD&index=2&md5=ebb3aae1609bc9d4d21980d854ad088b)\nresearch project, co-funded by the European Union Innovative Health Initiative\n(IHI\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ihi.europa.eu%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=IHI&index=3&md5=7077c59aab765eb05f10cae7d07fa3bb)\n) and industry partners. The research consortium is led by University Medical\nCenter Groningen (UMCG\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.umcg.nl%2Fover-het-umcg&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=UMCG&index=4&md5=ca5aad018997cfbcdf9c00368350eef0)\n) and Royal Philips\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.philips.com%2Fnewscenter&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=Royal+Philips&index=5&md5=088ddbf19aeb64ea1c22e5efad1fd903)\n, and aims to transform how cardiovascular disease is detected, monitored and\ntreated.\n\nWithin EXIT-CVD, the HEART-CHECK study will evaluate the HeartBeam System for\nearly detection and triage of cardiac events in high-risk patients recently\ndischarged after an acute coronary syndrome (ACS), a group with\nwell-documented risk of recurrent ischemic events, arrhythmias and hospital\nreadmissions(1).\n\n“Patients discharged after an ACS are in a vulnerable period, and their\nsymptoms can be atypical and easily dismissed,” said Branislav Vajdic, PhD,\nFounder and President of HeartBeam. “HEART-CHECK gives us the opportunity to\nevaluate whether a clinical-grade ECG recording outside of a medical facility\ncan help clinicians recognize recurrent events earlier and get these patients\nto the right care sooner. Our priority remains FDA clearance for heart attack\nassessment. HEART-CHECK builds on our heart attack detection work, as we\ncontinue to advance opportunities for heart attack assessment outside of the\nhealthcare facility. Being invited to contribute alongside some of the\nworld’s leading cardiovascular institutions and companies affirms the\nimportance of acting at the right point along the cardiac care journey.”\n\nHeartBeam’s role in the EXIT-CVD Consortium\n\nHeartBeam is a contributing partner in the EXIT-CVD consortium and will lead\nthe HEART-CHECK study, one of the project’s 22 clinical studies.\nHeartBeam’s contribution to the consortium is in-kind, including devices and\nclinical team expertise. The HEART-CHECK study is designed as a hybrid\neffectiveness-implementation study, assessing both the HeartBeam System’s\nclinical performance in the intended use population and its integration into\nreal-world care pathways. The HeartBeam System is currently not CE marked and\nwill be evaluated in HEART-CHECK for investigational purposes only.\n\nThe HeartBeam System captures the heart’s electrical signals in three\nnon-coplanar dimensions, delivering clinical-grade ECG data outside the\nhospital. Earlier this month, the U.S. Food and Drug Administration (FDA)\ngranted Breakthrough Device Designation to the HeartBeam System as a tool for\nassessing potential heart attacks at home. The HeartBeam System is currently\nFDA cleared for arrhythmia assessment only. Its use for heart attack\nassessment is investigational only at this time.\n\nEXIT-CVD aims to transform how cardiovascular disease is detected, monitored\nand treated. It will do so by identifying and acting on three key exit points\nalong the cardiac care journey: preventing disease before it develops (early\nexit), reversing disease progression (mid exit), or halting progression in\nadvanced stages (late exit). By combining diagnostics, digital tools and\nadvanced therapeutic approaches, EXIT-CVD aims to deliver actionable,\nevidence-based strategies that can be implemented across diverse healthcare\nsystems in Europe. The research project unites 42 public and private partners\nacross 17 countries to conduct 22 clinical studies involving more than 14,000\npatients. With a total budget of EUR 27.6 million, the project is co-funded by\nthe European Union Innovative Health Initiative (IHI) and industry partners.\n\n“Our vision is a future where heart disease is no longer an irreversible\npathway,” said Professor Pim van der Harst, Project Coordinator of EXIT-CVD\nand Head of Cardiology at the University Medical Center Groningen. “By\nunderstanding both the biological and social drivers of cardiovascular\ndisease, and deploying integrated innovations across diagnostics, monitoring,\nand care, we can empower patients and clinicians to exit the disease continuum\nbefore it’s too late.”\n\n“For more than 30 years, we have viewed cardiovascular disease as a\ncontinuous journey, from risk factors such as hypertension, to\natherosclerosis, a first cardiac event and ultimately, for many patients,\nheart failure,” said Robin Nijveldt, Chief of Cardiology at UMC Utrecht.\n“Yet most of us improve care within our own specialty and rarely have a\ncomplete view of the patient’s experience. EXIT-CVD is an ambitious effort\nto build that holistic view together, helping transform cardiac care for\nmillions of patients across Europe.”\n\nClinical studies\n\nThe EXIT-CVD research consortium will conduct a total of 22 clinical studies\ninvolving more than 14,000 patients across Europe, including:\n\n\n * Remote Cardiac Monitoring After Acute Coronary Syndrome (HEART-CHECK study):\nHybrid effectiveness-implementation study evaluating the HeartBeam System for\nearly detection and triage of acute coronary syndrome in high-risk\ncardiovascular patients.\n\n * Camera-Based In-Hospital Monitoring (CARDIO-CAM study): Deployment and\nevaluation of an unobtrusive, video-based patient monitoring system that\ncontinuously captures cardiorespiratory signals and relevant clinical context.\n\n * Spectral CT for Early Detection, Risk Stratification and Personalized Patient\nCare Pathways (LEADER-PAD study): Development and validation of new approaches\nfor the early detection of cardiovascular disease in asymptomatic and low risk\nsymptomatic patients using spectral CT.\n\n * Nurse/HCP-Led Remote Heart Failure Monitoring (REMODEL-HF study):\nMultinational randomized study evaluating the Heart Failure Management System\n(\nHFMS\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcardiac.zoll.com%2Fmedical-professionals%2Fheart-failure-management-system&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=HFMS&index=6&md5=a8cf3e2993163d4ddb9056004acbe505)\n\n), a non-invasive remote monitoring technology, in patients recently\nhospitalized for heart failure, with the objective of improving outcomes and\noptimizing guideline-directed medical therapy.\n\n * Imaging-Guided PCI Randomized Trial (GUIDANCE-PCCT study): Evaluation of\nclinical and procedural outcomes of PCI guided by photon counting CT versus\nstandard angiography-guided PCI.\n\n * Advanced Imaging in Infiltrative Cardiomyopathies (NOTIFY-2 study): Validation\nof AI-driven image and ECG analysis algorithms to improve early diagnosis of\nLeft Ventricular Hypertrophy (LVH) and underlying disease risk stratification.\n\nConsortium partners\n\nThe IHI EXIT-CVD public-private partnership comprises 42 partner organizations\nfrom 17 countries:\n\n\n * Clinical and academic partners: Hospital de la Santa Creu i Sant Pau (Spain),\nPolitecnico di Milano (Italy), University of Pavia (Italy), Centro\nCardiologico Monzino (Italy), EOC (Switzerland), KU Leuven (Belgium), NIKARD\n(Poland), UMC Utrecht (Netherlands), UMC Groningen (Netherlands), Technical\nUniversity Eindhoven (Netherlands), Universitätsklinikum Köln (Germany),\nKing’s College London (UK), London School of Economics and Political Science\n(UK), and Varsinais-Suomen Hyvinvointialue (Finland)\n\n * Industry partners: Philips, Circle CVI, GE HealthCare, Siemens Healthineers,\nHeartBeam, Medtronic, Huawei, XVIVO Perfusion, AstraZeneca, Cardiomed, Megi\nHealth, Viatris, Cordys, Novartis, Corbotics, ZOLL, Sanofi, Repairon, Johnson\n& Johnson MedTech Heart Recovery, Onsentia, and CogStack\n\n * Healthcare consultancy: Bridg Ou and IQVIA Solutions\n\n * Patient organization: Stichting VrouwenHart\n\n * Medical association: European Society of Cardiology (ESC)\n\nMore information can be viewed on the EXIT-CVD\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fexitcvd.eu%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=EXIT-CVD&index=7&md5=d5b8da513c295c46741b671c0afb9ee7)\nwebsite.\n\nThis project is supported by the Innovative Health Initiative Joint\nUndertaking (IHI JU) under grant agreement No 101253160. The JU receives\nsupport from the European Union's Horizon Europe research and innovation\nprogram and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.\nFunded by the European Union, the private members, and those contributing\npartners of the IHI JU. Views and opinions expressed are those of the\nauthor(s) only and do not necessarily reflect those of the aforementioned\nparties. Neither of the aforementioned parties can be held responsible for\nthem.\n\nAbout HeartBeam, Inc.\n\nHeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to\ntransforming the detection and monitoring of critical cardiac conditions. The\nCompany has developed the first-ever cable-free device capable of collecting\nECG signals in 3D, from three non-coplanar directions, and synthesizing the\nsignals into a 12-Lead ECG. This platform technology is designed for portable\ndevices that can be used wherever the patient is to deliver actionable heart\nintelligence. Physicians will be able to identify cardiac health trends and\nacute conditions and direct patients to the appropriate care – all outside\nof a medical facility, thus redefining the future of cardiac health\nmanagement. HeartBeam’s 3D ECG technology received FDA clearance for\narrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software\nreceived FDA clearance for arrhythmia assessment in December 2025(1). The\nCompany holds over 25 issued patents related to technology enablement. For\nadditional information, visit HeartBeam.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heartbeam.com%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=HeartBeam.com&index=8&md5=5eb9a383b2f58c45e0639bcc77d71d8a)\n.\n\nForward-Looking Statements\n\nAll statements in this release that are not based on historical fact are\n\"forward-looking statements.\" While management has based any forward-looking\nstatements included in this release on its current expectations, the\ninformation on which such expectations were based may change. Forward-looking\nstatements involve inherent risks and uncertainties which could cause actual\nresults to differ materially from those in the forward-looking statements, as\na result of various factors including those risks and uncertainties described\nin the Risk Factors and in Management’s Discussion and Analysis of Financial\nCondition and Results of Operations sections of our Forms 10-K, 10-Q and other\nreports filed with the SEC and available at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=www.sec.gov&index=9&md5=1503a652d53948613704053cc9dfbd1f)\n. We urge you to consider those risks and uncertainties in evaluating our\nforward-looking statements. We caution readers not to place undue reliance\nupon any such forward-looking statements, which speak only as of the date\nmade. Except as otherwise required by the federal securities laws, we disclaim\nany obligation or undertaking to publicly release any updates or revisions to\nany forward-looking statement contained herein (or elsewhere) to reflect any\nchange in our expectations with regard thereto or any change in events,\nconditions or circumstances on which any such statement is based.\n\n(1)Cleared Indications for Use\n\nThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia\nassessment received FDA clearance in December 2025. Refer to the Company’s\nCleared Indications for Use at https://www.heartbeam.com/indications\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heartbeam.com%2Findications&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=https%3A%2F%2Fwww.heartbeam.com%2Findications&index=10&md5=6463cd35978c51d77e0b2e314fd37a99)\nfor details on the intended use of its technology.\n\nMKT-166 v0\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261015343006/en/\n(https://www.businesswire.com/news/home/20261015343006/en/)\n\nMedia Contact: \n\nmedia@heartbeam.com (mailto:media@heartbeam.com)\n\nInvestor Relations Contact: \n\nChris Tyson\n\nExecutive Vice President\n\nMZ North America\n\nDirect: 949-491-8235\n\nBEAT@mzgroup.us \n(mailto:BEAT@mzgroup.us) \nwww.mzgroup.us\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.mzgroup.us%2F&esheet=54622656&newsitemid=20261015343006&lan=en-US&anchor=www.mzgroup.us&index=11&md5=332013f545ec9fef8335da154ea91295)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-15T12:31:00.192978785Z","server_sent_at_ms":1792067460192},"received_at":"2026-10-15T12:31:00.327Z","source_url":"https://www.businesswire.com/news/home/20261015343006/en/"},"analysis":{"id":"158554","press_release_id":"170364","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["HeartBeam System is not CE marked; HEART-CHECK participation is investigational only","contribution is in-kind — no direct revenue from the consortium"],"eventType":"partnership","narrative":"HeartBeam has joined the EU-funded EXIT-CVD research consortium alongside Philips, Medtronic, GE HealthCare and other global healthcare leaders, and will lead the HEART-CHECK study, one of the project's 22 clinical studies.\n\nHEART-CHECK will evaluate whether HeartBeam's at-home 3D ECG System can help clinicians detect recurrent cardiac events earlier in patients recently discharged after an acute coronary syndrome. HeartBeam's contribution is in-kind, and the System is not CE marked and is investigational in this setting.\n\nThe consortium comprises 42 partners across 17 countries, 22 studies and more than 14,000 patients, with a total budget of EUR 27.6 million co-funded by the EU Innovative Health Initiative. The company notes FDA recently granted Breakthrough Device Designation for at-home heart attack assessment, and FDA clearance for heart attack assessment remains its priority.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Credibility boost: HeartBeam leading a study in a top-tier EU cardiac consortium validates its 3D ECG platform, though financial impact is nil."},"keyFigures":{"customDimensions":{"countries":17,"clinical_studies":22,"patients_enrolled":"more than 14,000","project_budget_eur":"EUR 27.6 million","consortium_partners":42}},"quotedText":"Our priority remains FDA clearance for heart attack assessment. HEART-CHECK builds on our heart attack detection work, as we continue to advance opportunities for heart attack assessment outside of the healthcare facility.","namedEntities":{"people":[{"name":"Branislav Vajdic","role":"Founder and President of HeartBeam"},{"name":"Pim van der Harst","role":"Project Coordinator of EXIT-CVD, Head of Cardiology at UMCG"},{"name":"Robin Nijveldt","role":"Chief of Cardiology at UMC Utrecht"},{"name":"Chris Tyson","role":"Executive Vice President, MZ North America (IR)"}],"products":["HeartBeam System","HEART-CHECK study","EXIT-CVD"],"companies":[{"name":"HeartBeam, Inc.","ticker":"BEAT","relationship":"filer/consortium partner"},{"name":"Royal Philips","relationship":"consortium co-lead"},{"name":"University Medical Center Groningen (UMCG)","relationship":"consortium co-lead"},{"name":"Medtronic","relationship":"consortium partner"},{"name":"GE HealthCare","relationship":"consortium partner"},{"name":"Siemens Healthineers","relationship":"consortium partner"},{"name":"AstraZeneca","relationship":"consortium partner"},{"name":"Novartis","relationship":"consortium partner"},{"name":"Sanofi","relationship":"consortium partner"},{"name":"Johnson & Johnson MedTech Heart Recovery","relationship":"consortium partner"}],"dollarAmounts":[{"amount":"EUR 27.6 million","context":"total EXIT-CVD project budget"}]},"materialImpact":{"score":2,"reasoning":"HeartBeam joins a prestigious EU-funded consortium alongside Philips, Medtronic and GE HealthCare and will lead the HEART-CHECK study, providing validation and in-kind (not cash) contribution. No revenue, regulatory or financial impact; the study is investigational only."},"tickerRelevance":{"others":[],"primary":"BEAT"},"globalImportance":22,"audienceRelevance":20,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"cashImpact":"none (in-kind contribution)","tickerTier":"micro-cap","eventGravity":"consortium partnership with clinical validation potential","regulatoryAngle":"supports pending heart attack assessment clearance path"}},"event_type":"partnership","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"HeartBeam has joined the EU-funded EXIT-CVD research consortium alongside Philips, Medtronic, GE HealthCare and other global healthcare leaders, and will lead the HEART-CHECK study, one of the project's 22 clinical studies.\n\nHEART-CHECK will evaluate whether HeartBeam's at-home 3D ECG System can help clinicians detect recurrent cardiac events earlier in patients recently discharged after an acute coronary syndrome. HeartBeam's contribution is in-kind, and the System is not CE marked and is investigational in this setting.\n\nThe consortium comprises 42 partners across 17 countries, 22 studies and more than 14,000 patients, with a total budget of EUR 27.6 million co-funded by the EU Innovative Health Initiative. The company notes FDA recently granted Breakthrough Device Designation for at-home heart attack assessment, and FDA clearance for heart attack assessment remains its priority.","key_figures":{"customDimensions":{"countries":17,"clinical_studies":22,"patients_enrolled":"more than 14,000","project_budget_eur":"EUR 27.6 million","consortium_partners":42}},"named_entities":{"people":[{"name":"Branislav Vajdic","role":"Founder and President of HeartBeam"},{"name":"Pim van der Harst","role":"Project Coordinator of EXIT-CVD, Head of Cardiology at UMCG"},{"name":"Robin Nijveldt","role":"Chief of Cardiology at UMC Utrecht"},{"name":"Chris Tyson","role":"Executive Vice President, MZ North America (IR)"}],"products":["HeartBeam System","HEART-CHECK study","EXIT-CVD"],"companies":[{"name":"HeartBeam, Inc.","ticker":"BEAT","relationship":"filer/consortium partner"},{"name":"Royal Philips","relationship":"consortium co-lead"},{"name":"University Medical Center Groningen (UMCG)","relationship":"consortium co-lead"},{"name":"Medtronic","relationship":"consortium partner"},{"name":"GE HealthCare","relationship":"consortium partner"},{"name":"Siemens Healthineers","relationship":"consortium partner"},{"name":"AstraZeneca","relationship":"consortium partner"},{"name":"Novartis","relationship":"consortium partner"},{"name":"Sanofi","relationship":"consortium partner"},{"name":"Johnson & Johnson MedTech Heart Recovery","relationship":"consortium partner"}],"dollarAmounts":[{"amount":"EUR 27.6 million","context":"total EXIT-CVD project budget"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T12:31:07.161Z","global_importance":22,"audience_relevance":20,"importance_components":{"cashImpact":"none (in-kind contribution)","tickerTier":"micro-cap","eventGravity":"consortium partnership with clinical validation potential","regulatoryAngle":"supports pending heart attack assessment clearance path"}},"durationMs":6805,"modelName":"glm-5.3-flashx"}}